Robert L. Rosiello, Executive Vice President at Valeant Pharmaceuticals International, Inc. (VRX), bought 12,900 shares at $232.51 ($3.0M) on 2015-06-12, disclosed to the SEC on 2015-06-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.